Phase Space AI

Valuation

Boston Scientific [BSX]

Boston Scientific [BSX] — Valuation

Spot $46.04 · 2026-07-29 · Shares 1,484.9m diluted · Net DEBT $9,576m · EV $77,941m · EV/Sales 3.71x

---

COMPANY STATE: A — mature and structurally stable

Declared before the instrument was chosen, per valuation.md.

Test and evidence: - Profitable: GAAP operating income positive in every one of the last 11 fiscal years (2015–2025). - Operating margin low-variance across ≥5 years: GAAP EBIT margin 14.38% / 15.32% / 15.73% / 19.78% / 21.60% over FY2022–TTM — a 7.2pp band that is monotonically rising, not oscillating. Including FY2020 (6.06%, elective-procedure shutdown) widens it, and that observation is a documented exogenous shock, not margin instability. - No structural regime change: no business-model transition, no accounting-basis break, no transformative acquisition closed. BSX is a serial tuck-in acquirer — 250–390bp of revenue per year — which is a steady-state capital-allocation policy rather than a regime change.

Two qualifications recorded rather than buried: 1. Penumbra is pending, not closed. At ~$12.5bn it is ~15% of EV and would be the largest deal in BSX's modern history. Post-close, State A should be re-tested. Guidance and the EV in this memo both exclude it. 2. A growth-rate regime change is underway even though the margin regime is stable. Organic growth went 16% (FY2024, FY2025) → 6.5–8.0% guided (FY2026). State A governs the terminal margin instrument correctly; it does not license using the multiple history formed at the old growth rate (see below).

Consequence: fix the underwritten terminal margin from BSX's own normalised economics, solve for price-implied growth, show the sensitivity surface. Industry data is a sanity band, never an override. Evidence grade: A.

---

Terminal margin: 22.0% GAAP EBIT

Built from BSX's own demonstrated economics and its stated trajectory. Not a percentile, not a median, not a cap.

The opex bridge (terminal year FY2031, GAAP basis)

  m_gross,T                                       70.0%
  − R&D                                          (10.5%)
  − SG&A                                         (33.5%)
  − amortization of acquired intangibles          (3.0%)
  − other (royalties, restructuring, litigation)  (1.0%)
  ─────────────────────────────────────────────────────
  = m_EBIT,T                                      22.0%

Hard constraint check: m_EBIT,T 22.0% ≤ m_gross,T 70.0% — SATISFIED, with 48pp of headroom. The bridge is not merely arithmetically legal, it reconciles line by line.

Justification of each term

• m_gross,T = 70.0%. TTM actual is 71.16%; Q1 2026 adjusted gross margin was 70.5%. Management guides FY2026 adjusted gross margin "slightly below full year 2025", driven by tariffs, POLARx discontinuation inventory charges, and "incremental investments in our global supply chain and quality systems." 70.0% therefore sits slightly below the trailing actual — deliberately, with the named cause being a persistent tariff regime, not conservatism for its own sake.
• R&D 10.5%. TTM R&D $2,152m / $20,997m = 10.25%, and rising (FY2023 9.9%). BSX is funding FARAWAVE Ultra, FANAFLEX, the coronary IVL programme and CHAMPION follow-on evidence. Held slightly above trailing.
• SG&A 33.5%. FY2025 SG&A $6,888m / $20,074m = 34.3%. Management guides "OpEx leverage as we drive strong spend controls and continue to implement efficiency initiatives and optimize our organizational structure," delivering +50–75bp/yr of adjusted operating margin expansion. 80bp of SG&A leverage over five years is a fraction of what is guided — conservative.
• Amortization 3.0% and other 1.0%. These are the GAAP-vs-adjusted wedge. BSX's adjusted operating margin is ~29%; GAAP TTM is 21.6%. The 7.4pp gap is almost entirely acquired-intangible amortization, restructuring and litigation, and a serial tuck-in acquirer will keep incurring it. Carrying it is the reason this terminal margin is 22% and not 29% — and it is the right choice, because the exit multiple is applied to GAAP EBIT.

The mandated sanity test

Is the terminal margin below the company's own trailing actual? No — 22.0% vs 21.60% TTM, +0.4pp. This clears the constraint the brief flags (21 of 84 names previously carried terminal margins below their own trailing actual: XZO −26.9pp, AVGO −24.3pp, MSFT −23.7pp). It is deliberately modest rather than extrapolating the +5.9pp of GAAP margin expansion BSX delivered over the last three years, because the gross-margin tailwind that produced part of that has reversed into a tariff headwind.

---

Exit multiple: 16.0x EV/EBIT — growth-matched, two independent anchors

Exit-year growth

FY2026 guided organic 6.5–8.0%; weighted-average market growth rate stated at ~8%. Terminal-year (FY2031) growth underwritten at ~6%.

Comparator set — growth-matched, recorded in analysis.json

Requirements per valuation.md: n ≥ 5 mature profitable firms, matching operating model (diversified multi-franchise medical device), and dispersion in the dimension being matched.

Validity asserted: n=6, all mature and profitable, all diversified device platforms, growth spans 2.4%–10.3% and therefore brackets the underwritten 6% exit growth. Dispersion in the matched dimension is 7.9pp — this set carries information, unlike the 29.9x/29.9x/30.4x anchor recorded in known-silent-failures.md §9.9. Excluded and why: PEN (65.5x — a deal price, BSX is the acquirer), BAX and IRTC (negative EBIT, undefined multiple), TFX/ICUI (declining revenue, −6.6%/−10.9%, outside the bracket), ISRG/PODD/GMED/TMDX (20–32% growth, far outside), MASI/HOLX (AV returned no quarterly statements).

The second anchor — the warranted-multiple identity

EV_T/EBIT_T = (1−t)(1−g/ROIC)/(WACC−g). The exit multiple is not a free parameter.

Measured BSX ROIC: NOPAT = $4,535m × (1−0.20) = $3,628m; invested capital = equity $25,864m + net debt $9,576m = $35,440m → ROIC 10.2%. At t=0.20, g=4.5%, WACC=8.5%: 0.80 × (1 − 0.045/0.102) / 0.040 = 11.2x.

This is the most interesting number in the memo. BSX's warranted continuing multiple from its own reinvestment economics is ~11x, less than half the 23.8x its growth-matched peers trade at. The cause is identifiable: twenty years of acquisition goodwill sits in invested capital. BSX's incremental returns on tuck-in deals are plainly better than 10.2% — Farapulse alone proves that — but the measured whole-company ROIC is what the identity consumes, and it says the peer group is being paid for reinvestment quality BSX's balance sheet does not evidence.

Base multiple selection

16.0x sits above the identity anchor and below the comparator anchor, and marginally below BSX's own current multiple. It does not sit below every stated anchor — the NTRA defect (anchors of 7.0x/7.5x with a base of 5.0x) is explicitly avoided. Implied compression from today's 17.2x: −7.0%.

---

THE IMPLIED-PATH TEST — Valuation Criteria

reverse_dcf.py --spot 46.04 --shares 1484.9 --net-cash -9576 --revenue 20997 --years 5 --wacc 0.085 --terminal-margin 0.220 --exit-multiple 16.0 --solve cagr

Parameter solved for: revenue CAGR. Parameters held fixed: terminal margin 22.0%, exit multiple 16.0x, WACC 8.5%, horizon 5y, net debt $9,576m, shares 1,484.9m, TTM revenue $20,997m.

THE MARKET REQUIRES: 9.66% reported revenue CAGR

Demonstrated (3-year reported): 16.54%. MARGIN: +6.88pp.

Sensitivity over the exit multiple (the highest-variance parameter)

At the growth-matched comparator median of 23.8x the price requires only ~1.3%. At the identity-derived 11.2x it requires ~18.0% — above anything BSX will now deliver. The verdict is genuinely multiple-determined, and the flip point against the 16.54% demonstrated CAGR is 11.8x.

VERDICT: PASS

Not "PASS with argument" — PASS, and the reason is the organic-versus-reported work in the research document rather than optimism.

The required parameter is a reported revenue CAGR of 9.66%. BSX's reported growth has structurally exceeded organic growth by 250–390bp per year through tuck-in M&A, which is its stated first capital priority and which the CFO quantified at +350bp for FY2025. So:

  required reported CAGR                    9.66%
  − structural M&A contribution        (2.5–3.5pp)
  ─────────────────────────────────────────────────
  = required ORGANIC CAGR              6.2 – 7.2%

That sits inside the company's own FY2026 organic guidance of 6.5–8.0% and below the ~8% weighted-average market growth rate BSX competes in. The price is not asking BSX to reaccelerate. It is asking BSX to hold the growth rate it has already guided down to, and to keep doing the tuck-in M&A it has done every year for a decade. Against a business with 71% gross margins, $4bn of free cash flow and 1.8x leverage, that clears.

Correction to the screen's margin — an important defect

The screen recorded required 3.2% vs demonstrated 16.5% = +13.3pp. The true margin at a defensible exit multiple is +6.88pp. The 6.4pp overstatement decomposes as:

And separately — not an arithmetic error but a staleness error — the "16.5% demonstrated" is a trailing 3-year reported CAGR that management has already guided down to 6.5–8.0% organic. The margin should be read against forward capability, not trailing history, which is exactly what the PASS argument above does.

---

12-MONTH TARGET: $57.00 (+23.8%)

Built per valuation.md §"The 12-month target" — not a DCF, and not a peer median projected forward.

1. Near-term base. FY2026 guided reported revenue growth 7.0–8.5% on FY2025's $20,074m → $21,479–21,780m. NTM revenue (Q3 2026–Q2 2027) ≈ $21,900m. Penumbra excluded, consistent with guidance.

2. Multiple anchored on BSX's OWN trading history — with the regime break named.

BSX's own 8-year quarterly EV/Sales history (n=32, 2018-06-30 → 2026-03-31):

BSX trades at the 0th percentile of its own eight-year multiple history — below the trough it printed in the March-2020 elective-procedure shutdown.

The median and the trailing-8-quarter median (8.58x) are NOT admissible anchors. Every observation in that history was formed at 11–20% organic growth; FY2026 is guided at 6.5–8.0%. Using the own-median would produce a $122.50 target (+166%) by pricing a growth rate the company has retired — the precise error valuation.md warns about when history "spans a regime change."

Anchor adopted: 4.26x, the own-history minimum (0th percentile). It is corroborated independently by the growth-matched comparator median EV/Sales of 4.12x (table above) — two anchors, built from different data, agreeing within 3%. That agreement is what identifies the multiple.

3. Product-cycle events inside 12 months (all in the Catalyst Calendar with dates): Penumbra close (H2 2026); ~$2bn buyback executing from Q2 2026, reducing the share count to ~1,455m; peripheral IVL below-the-knee launch (H2 2026); FANAFLEX IDE initiation (2026); next-generation ureteroscope (2026); LAAC guideline consideration ahead of any NCD update (undated — not modelled).

4. Target. (4.26 × 21,900 − 9,576) / 1,455 = $57.52. Rounded to $57.00, +23.8% to spot. Target multiple 4.2x = ~2nd percentile of BSX's own 8-year history.

Sanity band. A +23.8% target on a name at the 0th percentile of its own multiple history is not an aggressive call — it assumes BSX merely stops trading below its worst-ever multiple. valuation.md records that a process producing every target below spot is expressing a house view rather than valuing companies; this target is above spot and the reason is that the price is below an eight-year floor.

---

Criteria summary